Ionis Pharmaceuticals (IONS) reported $203 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 10.6%. EPS of -$1.14 for the same period compares to -$0.66 a year ago.
The reported revenue represents a surprise of +30.48% over the Zacks Consensus Estimate of $155.58 million. With the consensus EPS estimate being -$1.21, the EPS surprise was +5.39%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total research and development revenue: $62 million versus $24.74 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -56% change.
- Revenue- Total commercial revenue: $141 million compared to the $127.06 million average estimate based on seven analysts. The reported number represents a change of +64% year over year.
- Revenue- Commercial revenue- Other commercial revenue: $8 million compared to the $7.17 million average estimate based on six analysts. The reported number represents a change of -33.3% year over year.
- Royalty revenue- SPINRAZA royalties: $54 million versus $58.45 million estimated by six analysts on average.
- Product sales, net: $57 million compared to the $40.46 million average estimate based on six analysts.
- Royalty revenue- WAINUA royalties: $16 million versus the six-analyst average estimate of $14.96 million.
- Royalty revenue: $76 million versus the six-analyst average estimate of $78.95 million.
- Revenue- Research and development revenue- Collaborative agreement revenue: $52 million versus the five-analyst average estimate of $16.75 million. The reported number represents a year-over-year change of -46.4%.
- Revenue- Research and development revenue- WAINUA joint development revenue: $10 million compared to the $11.64 million average estimate based on five analysts.
- Royalty revenue- Other royalties: $6 million versus $6.66 million estimated by five analysts on average.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>
Shares of Ionis Pharmaceuticals have returned +4% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
